Efficacy and safety of combination of tadalafil and aspirin versus tadalafil or aspirin alone in patients with vascular erectile dysfunction: A comparative randomized prospective study
dc.contributor.author | Bayraktar, Zeki | |
dc.contributor.author | Albayrak, Selami | |
dc.date.accessioned | 10.07.201910:49:13 | |
dc.date.accessioned | 2019-07-10T19:35:32Z | |
dc.date.available | 10.07.201910:49:14 | |
dc.date.available | 2019-07-10T19:35:32Z | |
dc.date.issued | 2019 | en_US |
dc.identifier.citation | Bayraktar, Z. ve Albayrak, S. (2019). Efficacy and safety of combination of tadalafil and aspirin versus tadalafil or aspirin alone in patients with vascular erectile dysfunction: A comparative randomized prospective study. International Urology and Nephrology, 51(9), 1491-1499. https://dx.doi.org/10.1007/s11255-019-02211-4 | en_US |
dc.identifier.issn | 0301-1623 | |
dc.identifier.issn | 1573-2584 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/827 | |
dc.identifier.uri | https://dx.doi.org/10.1007/s11255-019-02211-4 | |
dc.description.abstract | Purpose: We aimed to investigate the efficacy and safety of tadalafil, aspirin, and tadalafil + aspirin combination therapy in vascular erectile dysfunction (VED). Methods: A total of 336 patients were randomly divided into four groups (group 1, aspirin 100 mg/day, 126 patients; group 2, tadalafil 5 mg/day, 72 patients; group 3, tadalafil 5 mg + aspirin 100 mg, 72 patients; group 4, placebo, 66 patients). In all groups, the changes from baseline to end point in erectile function scores on the International Index of Erectile Function (IIEF-EF) and the number of patients who answered “yes” to questions 2 and 3 of the sexual encounter profile(SEP) were compared statistically. Results: The changes in IIEF-EF scores after treatment were 7.2 ± 4.4, 7.3 ± 4.3, 7.5 ± 4.4, and 2.0 ± 4.6 for group 1 (p < 0.0001), group 2 (p < 0.0001), group 3 (p < 0.0001), and group 4 (p = 0.0204), respectively. The change in SEP-2 ratios after treatment were 36.6%, 36.9%, 41.7%, and 9.4% for group 1 (p < 0.0001), group 2 (p < 0.0001), group 3 (p < 0.0001), and group 4 (p = 0.2925), respectively. The change in SEP-3 ratios after treatment was 46.6%, 49.2%, 53.7%, and 12.5% for group 1 (p < 0.0001), group 2 (p < 0.0001), group 3 (p < 0.0001), and group 4 (p = 0.1456), respectively. In group 2, both the number of patients who reported side effects (p < 0.0001) and stopped using the drug due to side effects (p < 0.05) were significantly higher than the control and others groups. Conclusions: Successful results were obtained by tadalafil and aspirin monotherapy and tadalafil + aspirin combination therapy in patients with VED. However, the least side effect was observed in the tadalafil + aspirin group. Aspirin can be used alone in the treatment of patients with VED, or combined with tadalafil to reduce side effects and increase success. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer Netherlands | en_US |
dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
dc.subject | Antiplatelet | en_US |
dc.subject | Aspirin | en_US |
dc.subject | Erectile Dysfunction | en_US |
dc.subject | Tadalafil | en_US |
dc.subject | Therapy | en_US |
dc.title | Efficacy and safety of combination of tadalafil and aspirin versus tadalafil or aspirin alone in patients with vascular erectile dysfunction: A comparative randomized prospective study | en_US |
dc.type | article | en_US |
dc.relation.ispartof | International Urology and Nephrology | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-2493-2457 | en_US |
dc.authorid | 0000-0002-4245-7506 | en_US |
dc.identifier.volume | 51 | en_US |
dc.identifier.issue | 9 | en_US |
dc.identifier.startpage | 1491 | en_US |
dc.identifier.endpage | 1499 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1007/s11255-019-02211-4 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.identifier.scopusquality | Q2 | en_US |
Bu öğenin dosyaları:
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Makale Koleksiyonu [3649]
Article Collection -
PubMed İndeksli Yayınlar Koleksiyonu [4047]
PubMed Indexed Publications Collection -
Scopus İndeksli Yayınlar Koleksiyonu [6283]
Scopus Indexed Publications Collection -
WoS İndeksli Yayınlar Koleksiyonu [6432]
WoS Indexed Publications Collection